Trastuzumab in Primary Inflammatory Breast Cancer (IBC): High Pathological Response Rates and Improved Outcome.
about
Developmental therapeutics for inflammatory breast cancer: Biology and translational directionsTumor stromal vascular endothelial growth factor A is predictive of poor outcome in inflammatory breast cancer.Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin).Outcomes After Multidisciplinary Treatment of Inflammatory Breast Cancer in the Era of Neoadjuvant HER2-directed Therapy.Construction of an miRNA-regulated drug-pathway network reveals drug repurposing candidates for myasthenia gravis.Optimal sequencing of anti-HER2 therapy throughout the continuum of HER2-positive breast cancer: evidence and clinical considerations.
P2860
Trastuzumab in Primary Inflammatory Breast Cancer (IBC): High Pathological Response Rates and Improved Outcome.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Trastuzumab in Primary Inflamm ...... e Rates and Improved Outcome.
@ast
Trastuzumab in Primary Inflamm ...... e Rates and Improved Outcome.
@en
Trastuzumab in Primary Inflammatory Breast Cancer
@nl
type
label
Trastuzumab in Primary Inflamm ...... e Rates and Improved Outcome.
@ast
Trastuzumab in Primary Inflamm ...... e Rates and Improved Outcome.
@en
Trastuzumab in Primary Inflammatory Breast Cancer
@nl
prefLabel
Trastuzumab in Primary Inflamm ...... e Rates and Improved Outcome.
@ast
Trastuzumab in Primary Inflamm ...... e Rates and Improved Outcome.
@en
Trastuzumab in Primary Inflammatory Breast Cancer
@nl
P2093
P2860
P1433
P1476
Trastuzumab in Primary Inflamm ...... e Rates and Improved Outcome.
@en
P2093
Ana M Gonzalez-Angulo
Anthony Lucci
Gabriel N Hortobagyi
Kristine Broglio
Massimo Cristofanilli
Shaheenah Dawood
Thomas A Buchholz
Vicente Valero
P2860
P304
P356
10.1111/J.1524-4741.2010.00953.X
P577
2010-07-06T00:00:00Z